Tissue-Specific Oncogenic Activity of KRASA146T
Name
nihms-1526647.pdf
Description
Accepted version
Size
3.2 MB
Format
Adobe PDF
Checksum (MD5)
3238e3d5d88bb98203e094deb130ec13
Author(s)
Poulin, Emily J.
Bera, Asim K.
Lu, Jia
Lin, Yi-Jang
Strasser, Samantha Dale
Paulo, Joao A.
Huang, Tannie Q.
Morales, Carolina
Yan, Wei
Cook, Joshua
Date Issued
April 2019
Journal
Cancer Discovery
Publisher
American Association for Cancer Research (AACR)
Citation
Poulin, Emily J. et al. "Tissue-Specific Oncogenic Activity of KRASA146T." Cancer Discovery 9, 6 (April 2019): 738-755 © 2019 American Association for Cancer Research Inc
Version
Author's final manuscript
Abstract
KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRASG12D, a common mutant form, and KRASA146T, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRASA146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor– induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRASG12D and KRASA146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1158/2159-8290.cd-18-1220
